Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Genmab US, Inc., and MorphoSys US, Inc.

Cancer Summaries and Commentaries: Report from Atlanta on Advances in the Treatment of DLBCL

Release Date: December 23, 2021
Expiration Date: December 23, 2022

Activity Overview

This online activity is designed to update clinicians on data presented at the 63rd American Society of Hematology (ASH) Annual Meeting held December 11-14, 2021, in Atlanta, Georgia, and will help facilitate critical assessment and clinical integration of new evidence, when appropriate. The activity reviews 8 abstracts from ASH 2021 that focus on diffuse large B-cell lymphoma. For each abstract, a text summary of key clinical data is accompanied by perspectives from expert thought leaders who provide insights into how clinicians can apply these findings to their clinical practice to improve patient care.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Genmab US, Inc., and MorphoSys US, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is directed toward medical oncologists and hematologists who treat patients with DLBCL. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals (HCPs) involved in the management of patients with DLBCL will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the study design and rationale of recent clinical trials evaluating targeted and cellular therapies for the treatment of DLBCL in different settings
  • Assess practice-changing results from recent trials that have evaluated targeted and cellular therapies for the treatment of DLBCL
  • Evaluate recent clinical trial evidence on targeted and cellular therapies within the context of evolving treatment paradigms for patients with DLBCL

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies. 


Alberto Chiappori, MD
Christopher R. Flowers, MD, MS, FASCO
Division head ad interim, Division of Cancer Medicine
Chair & Professor, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Consultant: AbbVie, Bayer Healthcare, BeiGene, Celgene Corp, Denovo Biopharma, Epizyme, Genentech/Roche, Genmab, Gilead Sciences, Karyopharm, Pharmacyclics/Janssen Pharmaceuticals, SeaGen, Spectrum Pharmaceuticals; Grant/Research Support: 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen Pharmaceuticals, Kite, MorphoSys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda Oncology, TG Therapeutics, Xencor, Ziopharm, Burroughs Wellcome Fund, Eastern Cooperative Oncology Group, National Cancer Institute, Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research.

W. Victoria Lai, MD
Laurie H. Sehn, MD, MPH
Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Vancouver, Canada

Disclosures: Grant/Research Support: Roche; Consultant: Roche/Genentech, Incyte, AbbVie, Kite.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By